UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Annals of oncology, 2012-10, Vol.23 (10), p.2605-2612

2012

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients

Journal of cancer research and clinical oncology, 2023-08, Vol.149 (10), p.7155-7164

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

Annals of oncology, 2012-09, Vol.23 (9), p.2265-2271

2012

Link zum Volltext

Verfügbarkeit prüfen

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

Gynecologic oncology, 2019-02, Vol.152 (2), p.235-242

2019

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study

Annals of oncology, 2012-09, Vol.23 (9), p.2259-2264

2012

Link zum Volltext

Verfügbarkeit prüfen

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

Gynecologic oncology, 2019-11, Vol.155 (2), p.186-191

2019

Link zum Volltext

Verfügbarkeit prüfen

Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer

Journal of cancer research and clinical oncology, 2021-05, Vol.147 (5), p.1421-1430

2021

Link zum Volltext

Verfügbarkeit prüfen

Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Annals of oncology, 2018-10, Vol.29, p.viii340-viii340

2018

Link zum Volltext

Verfügbarkeit prüfen

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

The New England journal of medicine, 2023-06, Vol.388 (23), p.2145-2158

2023

Link zum Volltext

Verfügbarkeit prüfen

Prevalence, Spectrum and Antibiotic Susceptibility of Bacterial and Candida Colonization between the 21st and 33rd Week of Gestation in Women with PPROM – 5 Yearsʼ Experience in 1 Perinatal Center

Geburtshilfe und Frauenheilkunde, 2013-01, Vol.73 (1), p.59-62

2013

Link zum Volltext

Verfügbarkeit prüfen

Simultanes Auftreten eines Myelodysplastischen Syndroms und eines Adenokarzinoms der Tuba uterina

Geburtshilfe und Frauenheilkunde, 2016, Vol.76 (10)

2016

Link zum Volltext

Verfügbarkeit prüfen

Indications for the sentinel node: multicentric, size of tumor, prior surgery

Breast cancer online, 2008-02, Vol.11 (2), Article e3

2008

Link zum Volltext

Verfügbarkeit prüfen

Seltene gynäkologische Tumoren

Der Onkologe, 2009-03, Vol.15 (3), p.261-269

2009

Link zum Volltext

Verfügbarkeit prüfen

Correlation of acid ceramidase (AC), a key enzyme of the sphingolipid metabolism, with prognosis in epithelial ovarian cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15562-e15562

2011

Link zum Volltext

Verfügbarkeit prüfen

Disseminated tumor cells in the bone marrow of ductal carcinoma in situ patients

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.10582-10582

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.566-566

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer

Geburtshilfe und Frauenheilkunde, 2020, Vol.80 (10)

2020

Link zum Volltext

Verfügbarkeit prüfen

The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5088-5088

2011

Link zum Volltext

Verfügbarkeit prüfen

Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.615-615

2011

Link zum Volltext

Verfügbarkeit prüfen

Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5093-5093

2011

Link zum Volltext

Verfügbarkeit prüfen

What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5106-5106

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5035-5035

2010

Link zum Volltext

Verfügbarkeit prüfen

Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5052-5052

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(94)

Publikationsform

Artikel
(81)
Tagungsberichte
(22)

Sprache

Englisch
(86)
Deutsch
(19)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Overexpression of the orphan nuclear receptor NR2F6 is associated with improved survival across molecular subgroups in endometrial cancer patients

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG)

Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer

Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Prevalence, Spectrum and Antibiotic Susceptibility of Bacterial and Candida Colonization between the 21st and 33rd Week of Gestation in Women with PPROM – 5 Yearsʼ Experience in 1 Perinatal Center

Simultanes Auftreten eines Myelodysplastischen Syndroms und eines Adenokarzinoms der Tuba uterina

Indications for the sentinel node: multicentric, size of tumor, prior surgery

Seltene gynäkologische Tumoren

Correlation of acid ceramidase (AC), a key enzyme of the sphingolipid metabolism, with prognosis in epithelial ovarian cancer

Disseminated tumor cells in the bone marrow of ductal carcinoma in situ patients

Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer

Safety and efficacy of the anti-PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer

The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5

Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer

Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group

What do primary and recurrent ovarian cancer patients (OC) expect from their doctors? Final results of a German survey in 608 patients

Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer

Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial

Suchergebnisse filtern